Aurelie Olivier
Overview
Explore the profile of Aurelie Olivier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
619
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwarz T, Hwang S, Ylisastigui P, Liu C, Takazawa K, Yono M, et al.
J Infect Dis
. 2024 Jul;
230(1):e102-e110.
PMID: 39052726
Background: The recently approved AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) demonstrated high efficacy against RSV-related disease in ≥60-year-olds. Methods: This ongoing phase...
2.
Ferguson M, Murray A, Pliamm L, Rombo L, Berglund J, David M, et al.
Vaccine X
. 2024 May;
18:100494.
PMID: 38746060
Background: Previous phase 3 studies showed that the AS01-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated...
3.
Ison M, Papi A, Athan E, Feldman R, Langley J, Lee D, et al.
Clin Infect Dis
. 2024 Jan;
78(6):1732-1744.
PMID: 38253338
Background: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety...
4.
Chandler R, Montenegro N, Llorach C, Aguirre L, Germain S, Kuriyakose S, et al.
Clin Infect Dis
. 2024 Jan;
PMID: 38189778
Background: Co-administration of vaccines against respiratory syncytial virus (RSV) and influenza can be considered given their overlapping seasonality, and may increase vaccine uptake and compliance. In this phase 3, open-label,...
5.
Francois B, Lambden S, Gibot S, Derive M, Olivier A, Cuvier V, et al.
BMJ Open
. 2021 Jul;
11(7):e042921.
PMID: 34233965
Introduction: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%....
6.
Francois B, Wittebole X, Ferrer R, Mira J, Dugernier T, Gibot S, et al.
Intensive Care Med
. 2020 May;
46(7):1425-1437.
PMID: 32468087
Purpose: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics...
7.
Cuvier V, Lorch U, Witte S, Olivier A, Gibot S, Delor I, et al.
Br J Clin Pharmacol
. 2018 Jun;
84(10):2270-2279.
PMID: 29885068
Aims: The peptide nangibotide is the first clinical-stage agent targeting the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1) and is being investigated as a novel therapy for acute inflammatory...
8.
Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A, et al.
N Engl J Med
. 2012 Nov;
367(24):2284-95.
PMID: 23136909
Background: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3...
9.
Olivier A, Sainz-Perez A, Dong H, Sparwasser T, Majlessi L, Leclerc C
Eur J Immunol
. 2011 May;
41(8):2303-13.
PMID: 21538349
TLR agonists have been suggested to directly impact Tregs, thereby enhancing or reversing their suppressive function. Here, in order to select TLR agonists leading to potent effector T-cell responses, while...
10.
Agnandji S, Fendel R, Mestre M, Janssens M, Vekemans J, Held J, et al.
PLoS One
. 2011 Apr;
6(4):e18559.
PMID: 21494604
Unlabelled: The recombinant circumsporozoite protein (CS) based vaccine, RTS,S, confers protection against Plasmodium falciparum infection in controlled challenge trials and in field studies. The RTS,S recombinant antigen has been formulated...